Katherine K. Matthay

39.3k total citations · 10 hit papers
302 papers, 26.5k citations indexed

About

Katherine K. Matthay is a scholar working on Neurology, Cancer Research and Molecular Biology. According to data from OpenAlex, Katherine K. Matthay has authored 302 papers receiving a total of 26.5k indexed citations (citations by other indexed papers that have themselves been cited), including 226 papers in Neurology, 109 papers in Cancer Research and 102 papers in Molecular Biology. Recurrent topics in Katherine K. Matthay's work include Neuroblastoma Research and Treatments (225 papers), Cancer, Hypoxia, and Metabolism (106 papers) and Cancer therapeutics and mechanisms (79 papers). Katherine K. Matthay is often cited by papers focused on Neuroblastoma Research and Treatments (225 papers), Cancer, Hypoxia, and Metabolism (106 papers) and Cancer therapeutics and mechanisms (79 papers). Katherine K. Matthay collaborates with scholars based in United States, Switzerland and France. Katherine K. Matthay's co-authors include Robert C. Seeger, John M. Maris, Wendy B. London, Hiroyuki Shimada, Daniel O. Stram, Robert B. Gerbing, Susan L. Cohn, C. Patrick Reynolds, Judith G. Villablanca and Garrett M. Brodeur and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Katherine K. Matthay

298 papers receiving 26.0k citations

Hit Papers

Treatment of High-Risk Ne... 1991 2026 2002 2014 1999 1991 2008 2010 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid
    1999 1.4k citations Katherine K. Matthay, Judith G. Villablanca et al. profile →
  2. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
    1991 1.3k citations Katherine K. Matthay et al. profile →
  3. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
    2008 1.3k citations Susan L. Cohn, Andrew D.J. Pearson et al. Journal of Clinical Oncology profile →
  4. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
    2010 1.2k citations Alice L. Yu, Andrew L. Gilman et al. profile →
  5. Neuroblastoma
    2016 897 citations Katherine K. Matthay, John M. Maris et al. profile →
  6. The International Neuroblastoma Pathology Classification (the Shimada system)
    1999 739 citations Hiroyuki Shimada, Louis P. Dehner et al. Cancer profile →
  7. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
    2008 678 citations Tom Monclair, Garrett M. Brodeur et al. Journal of Clinical Oncology profile →
  8. Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
    2009 621 citations Katherine K. Matthay, Robert C. Seeger et al. Journal of Clinical Oncology profile →
  9. Advances in Risk Classification and Treatment Strategies for Neuroblastoma
    2015 611 citations Katherine K. Matthay, Wendy B. London et al. Journal of Clinical Oncology profile →
  10. Advancing therapy for neuroblastoma
    2022 203 citations Katherine K. Matthay et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine K. Matthay United States 85 19.0k 10.9k 8.0k 4.7k 3.8k 302 26.5k
John M. Maris United States 83 15.7k 0.8× 13.6k 1.2× 8.4k 1.1× 6.3k 1.3× 2.3k 0.6× 472 26.5k
Wendy B. London United States 69 12.0k 0.6× 7.1k 0.7× 4.9k 0.6× 3.9k 0.8× 2.5k 0.7× 276 17.4k
Robert C. Seeger United States 83 15.5k 0.8× 12.2k 1.1× 6.5k 0.8× 5.4k 1.1× 1.5k 0.4× 220 23.6k
C. Patrick Reynolds United States 74 9.7k 0.5× 12.7k 1.2× 4.8k 0.6× 5.0k 1.1× 1.1k 0.3× 338 21.8k
Nai‐Kong V. Cheung United States 69 7.7k 0.4× 6.8k 0.6× 3.0k 0.4× 5.5k 1.2× 1.0k 0.3× 392 16.7k
Peter C. Burger United States 94 10.3k 0.5× 14.6k 1.3× 6.5k 0.8× 5.0k 1.1× 3.6k 0.9× 361 43.0k
Allan H. Friedman United States 75 5.2k 0.3× 7.2k 0.7× 4.6k 0.6× 5.6k 1.2× 2.3k 0.6× 345 25.7k
Andrew D.J. Pearson United Kingdom 54 6.9k 0.4× 5.4k 0.5× 3.1k 0.4× 2.3k 0.5× 1.2k 0.3× 224 11.4k
Arie Perry United States 85 11.4k 0.6× 11.8k 1.1× 6.8k 0.8× 3.8k 0.8× 3.7k 1.0× 381 40.1k
Roger J. Packer United States 91 10.1k 0.5× 8.1k 0.7× 1.7k 0.2× 2.5k 0.5× 2.5k 0.7× 465 27.6k

Countries citing papers authored by Katherine K. Matthay

Since Specialization
Citations

This map shows the geographic impact of Katherine K. Matthay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine K. Matthay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine K. Matthay more than expected).

Fields of papers citing papers by Katherine K. Matthay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine K. Matthay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine K. Matthay. The network helps show where Katherine K. Matthay may publish in the future.

Co-authorship network of co-authors of Katherine K. Matthay

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine K. Matthay. A scholar is included among the top collaborators of Katherine K. Matthay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine K. Matthay. Katherine K. Matthay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hogarty, Michael D., David S. Ziegler, Andrea Franson, et al.. (2024). Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. British Journal of Cancer. 130(5). 788–797. 10 indexed citations
2.
Matthay, Katherine K., Mohammed Khattab, Shui Yen Soh, et al.. (2022). Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource‐limited countries. Pediatric Blood & Cancer. 69(4). e29568–e29568. 6 indexed citations
3.
Vo, Kieuhoa T., Steven G. DuBois, John Neuhaus, et al.. (2022). Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood & Cancer. 69(9). e29616–e29616. 5 indexed citations
4.
Yu, Alice L., Andrew L. Gilman, M. Fevzi Özkaynak, et al.. (2021). Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research. 27(8). 2179–2189. 132 indexed citations
5.
Campbell, Kevin, Derek Shyr, Rochelle Bagatell, et al.. (2019). Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood & Cancer. 66(8). e27819–e27819. 25 indexed citations
6.
Braunstein, Steve, Wendy B. London, Susan G. Kreissman, et al.. (2019). Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study. Pediatric Blood & Cancer. 66(7). e27736–e27736. 9 indexed citations
7.
Villablanca, Judith G., Lingyun Ji, Araz Marachelian, et al.. (2018). Predictors of response, progression‐free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high‐risk neuroblastoma. Pediatric Blood & Cancer. 65(5). e26940–e26940. 7 indexed citations
8.
Vo, Kieuhoa T., C. Lorrie Epling, Elizabeth Sinclair, et al.. (2016). Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(14). 3643–3650. 17 indexed citations
9.
DuBois, Steven G., Steven L. Allen, Joan F. Hilton, et al.. (2015). Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. British Journal of Cancer. 112(4). 644–649. 44 indexed citations
10.
More, Swati S., Melissa Itsara, Xiao-Dong Yang, et al.. (2011). Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems. Clinical Cancer Research. 17(8). 2339–2349. 51 indexed citations
11.
London, Wendy B., Mary Lou Schmidt, Steven G. DuBois, et al.. (2011). Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age. Journal of Clinical Oncology. 29(33). 4358–4364. 48 indexed citations
12.
London, Wendy B., Victoria Castel, Tom Monclair, et al.. (2011). Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology. 29(24). 3286–3292. 229 indexed citations
13.
Mueller, Sabine, Xiaodong Yang, Theo Sottero, et al.. (2011). Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Letters. 306(2). 223–229. 60 indexed citations
14.
Peuchmaur, Michel, Emanuele S. G. d'Amore, Vijay Joshi, et al.. (2003). Revision of the International Neuroblastoma Pathology Classification. Cancer. 98(10). 2274–2281. 173 indexed citations
15.
Goto, Shoko, Robert B. Gerbing, Daniel O. Stram, et al.. (2001). Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer. 92(10). 2699–2708. 98 indexed citations
16.
Rudnick, Emily F., Yasmin Khakoo, Nuno Lobo Antunes, et al.. (2001). Opsoclonus‐myoclonus‐ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies—a report from the children's cancer group study. Medical and Pediatric Oncology. 36(6). 612–622. 140 indexed citations
17.
Matthay, Katherine K. & Daniel O. Stram. (2000). IS ADJUVANT THERAPY EVER WARRANTED IN LOCALIZED NEUROBLASTOMA. ˜The œAmerican journal of pediatric hematology/oncology. 22(5). 399–402. 5 indexed citations
18.
DuBois, Steven G., John N. Lukens, Garrett M. Brodeur, et al.. (1999). Metastatic Sites in Stage IV and IVS Neuroblastoma Correlate With Age, Tumor Biology, and Survival. Journal of Pediatric Hematology/Oncology. 21(3). 181–189. 314 indexed citations
19.
Donnelly, Lane F., et al.. (1996). Renal cell carcinoma after therapy for neuroblastoma.. American Journal of Roentgenology. 167(4). 915–917. 21 indexed citations
20.
Matthay, Katherine K., Harland N. Sather, Robert C. Seeger, G M Haase, & G. Denman Hammond. (1989). Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy.. Journal of Clinical Oncology. 7(2). 236–244. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John M. Maris Breakdown of academic impact, for papers by Wendy B. London Breakdown of academic impact, for papers by Robert C. Seeger Breakdown of academic impact, for papers by C. Patrick Reynolds Breakdown of academic impact, for papers by Nai‐Kong V. Cheung Breakdown of academic impact, for papers by Peter C. Burger Breakdown of academic impact, for papers by Allan H. Friedman Breakdown of academic impact, for papers by Andrew D.J. Pearson Breakdown of academic impact, for papers by Arie Perry Breakdown of academic impact, for papers by Roger J. Packer
Rankless by CCL
2026